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Abstract 
Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. 
Severity refers to the loss of function of the organs induced by the disease process or to the occurrence 
of severe acute exacerbations. Severity may vary over time and needs regular follow up. Control is the 
degree to which therapy goals are currently met. These concepts have evolved over time for asthma in 
guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of 
the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases 
(rhinitis, chronic rhinosinusitis, chronic urticaria, atopic dermatitis) in order to have a uniform 
definition of severity, control and risk, usable in most situations. It is based on the appropriate 
diagnosis, availability and accessibility of treatments, treatment responsiveness and associated factors 
such as co-morbidities and risk factors. This uniform definition will allow a better definition of the 
phenotypes of severe allergic (and related) diseases for clinical practice, research (including 
epidemiology), public health purposes, education and the discovery of novel therapies. 
Key words 
IgE, allergy, severity, control, risk, asthma, rhinitis, rhinosinusitis, urticaria, atopic dermatitis 
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ACQ: Asthma Control Questionnaire 
ACT: Asthma Control Test 
AD: Atopic dermatitis 
ARIA: Allergic Rhinitis and its Impact on Asthma 
ATS: American Thoracic Society 
CRS: Chronic rhinosinusitis 
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U-BIOPRED: Unbiased BIOmarkers for the PREDiction of respiratory disease outcomes 
VAS: Visual analogue scale 
WAO:World Allergy Organization 
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Introduction 
Allergic diseases represent the world’s most common chronic disease. Several mechanisms are 
involved, but many result from IgE-mediated reactions (1). Not all sensitized patients are symptomatic 
(2) and symptom severity varies from mild to severe and from intermittent to persistent whereas 
exacerbations may occur in any patient regardless of severity. Most patients have an early onset of 
symptoms but the clinical phenotypes of allergic diseases may vary with age (3).  
Acute, IgE-mediated, severe reactions (e.g. anaphylaxis (4)) occurring in patients sensitized to drugs 
(5), foods (6) or hymenoptera venoms (7) may be life-threatening. Many types of acute non-IgE-
mediated allergic diseases or non-allergic diseases (1) such as aspirin hypersensitivity, hereditary 
angioedema (8), cold urticaria (9) or skin reactions such as DRESS (Drug Rash with Eosinophilia and 
Systemic Symptoms) or Lyell syndrome (10) may also be life-threatening. Acute allergic (and related) 
diseases will not be considered in this document. 
Major IgE-mediated chronic diseases include rhinitis (and conjunctivitis) (11), asthma (12), atopic 
dermatitis (13) and gastro-intestinal diseases. However, allergy is not the only mechanism involved 
(14-17). The present document will propose the definition of the severity of allergic and related (non-
allergic origin) diseases: asthma, rhinitis (conjunctivitis), rhinosinusitis (18-20), atopic dermatitis and 
chronic urticaria (21, 22). Occupational diseases will not be considered in this document. Atopic and 
vernal conjunctivitis are severe diseases which may affect the vision. They will be considered in an 
update of this document. 
Co-morbidities play a major role in severity, adding to the complexity of the disease and its 
management (11). However, in the current document, each disease will be considered separately since 
certain patients may have a severe disease (e.g. rhinitis) associated with a milder one (e.g. asthma).  
Concepts of disease severity, activity, control and responsiveness to treatment are linked. Severity 
refers to the loss of function of the organs induced by the disease process. It may vary over time and 
needs regular follow up. Activity refers to the current level of activation of the biological network 
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perturbations that cause the disease and their clinical consequences. Control is the degree to which 
therapy goals are currently met. Disease activity and control can be viewed as opposites. 
These concepts have evolved over time for asthma in the development of guidelines (23, 24), task 
forces (25) or consensus meetings (26). Up to 2006, asthma was classified by severity alone. Then, 
newer GINA guidelines replaced “grading by severity” with “grading by control” using the same 
items. Neither classification seems adequate when employed in isolation, nor is the classification of 
asthma by control alone sufficient (26). The NAEPP-EPR3 guidelines (23) made key suggestions 
combining impairment, response to treatment and risks. This concept was adopted by GINA (27). The 
uniform definition of severe asthma presented to WHO (28) was based on the NAEPP-EPR3 approach 
(23).  
The aim of this paper is to generalize the approach of the uniform definition of severe asthma 
presented to WHO (28) for allergic and related diseases in order to develop a uniform definition of 
severity, control and risk, usable in most situations. This uniform definition will enable a better 
definition of severe allergic (and related) diseases for clinical practice, research (including 
epidemiology), public health purposes, education and the discovery of novel therapies (Table I). 
1. Severity, control, response to treatment and risk in asthma 
The stratification and grading of asthma severity includes several components (Table 2). The most 
useful concept of asthma severity is based on the intensity of the treatment required to obtain control 
(26). 
1.1. Control 
The level of asthma control incorporates current clinical control and exacerbations over the past 6 to 
12 months (26). The measurement of current asthma control may be assessed by individual outcome 
measures such as daily or nocturnal symptoms, symptoms linked to activities or exercise, monitoring 
of peak flow or pulmonary function, as-needed use of relievers, and exacerbations. Used individually, 
these measures cannot accurately assess asthma control. A composite measure reflecting all key 
endpoints is more relevant (30) and has been used in guidelines (23, 2008 #27059, 31) (Table 3).   
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Several scores for the control of asthma have been validated and translated into many languages in 
adults and adolescents. Examples are:   
• The Royal College of Physicians’ three questions (32). 
• The Juniper’s Asthma Control Questionnaire (ACQ), based on 6 questions (ACQ6) and FEV1 
(ACQ7) (33). ACQ6 is more predictive than ACQ7 for asthma control  (34). 
• The Asthma Control Test (ACT), based on 5 questions (35, 36). 
In children, a few asthma control questionnaires have been validated (37, 38).  
None of these questionnaires appropriately assess exacerbations that are of importance in the 
assessment of the control of asthma and deserve further attention. 
Biomarkers hold  promise to capture complementary information regarding diagnosis and risk, but 
need to be validated with regard to control. Biomarkers are either not readily available or completely 
unavailable in most practice settings (39). 
Although asthma therapy is primarily aimed at controlling the disease, the control level of asthma is 
independent of the step of asthma treatment. Control can be achieved at any severity level. A patient 
under total control may still have severe disease (e.g. an oral corticosteroid-treated patient). Patients 
achieving control with treatment have a lower risk of exacerbation than those who are uncontrolled 
(39). 
1.2. Response to treatment 
Responsiveness to treatment has been demonstrated in studies assessing risk reduction during 
treatment. Studies at the community level show a considerable reduction of hospitalizations and deaths 
using appropriate management (40). Successful studies have been carried out in low- and middle- 
income countries (LMICs) (41, 42) or in deprived populations (43). The concept is therefore 
applicable to all populations and all countries. In the NAEPP-EPR3 guidelines (23), resistance to 
therapy is defined as uncontrolled asthma despite high-dose inhaled corticosteroids. For the 
INNOVATE trial (omalizumab), the European Medical Agency requested the assessment of asthma 
control in patients treated by inhaled corticosteroids and long-acting ß-agonists (44).  
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1.3. Risk 
The concept of asthma risk (23) is intended to capture: 
 The likelihood of future asthma exacerbations.  
 Progressive loss of pulmonary function over time (or for children, reduced lung growth).  
 Risk of adverse effects from treatment, which should always be considered carefully.  
These domains respond differentially to treatment. The assessment of risk domain is more difficult 
than the evaluation of control.   
1.4. Definition of asthma severity and control   
The definition of asthma severity, control and exacerbations proposed to WHO (28) took guidelines 
(23, 24) and the 2008 ATS/ERS Task Force report into consideration (26) (Figure 1). The recent 
consensus by U-BIOPRED (Unbiased BIOmarkers for the PREDiction of respiratory disease 
outcomes) from the Innovative Medicines Initiative (IMI) distinguishes severe asthma from alternative 
diagnoses by providing a stepwise algorithm to single out severe refractory asthma from difficult 
asthma based on insufficient therapy, poor treatment adherence and/or co-morbidity (45). 
In patients appropriately diagnosed, severe asthma is defined by the level of current clinical control 
and risks as: “Uncontrolled asthma which can result in risk of frequent severe exacerbations (or death) 
and/or adverse reactions to medications and/or chronic morbidity (including impaired lung function or 
reduced lung growth in children)” (28). 
This proposal also includes wheezing disorders in pre-school children although there is dispute as to 
the age at which the label “asthma” can properly be applied (46, 47). A consensus has been proposed 
(48), but the conclusions are still under discussion.  
2. Uniform approach to the severity of chronic allergic (and 
related) diseases 
Severe allergic (and related) diseases include 7 groups, each carrying different public health 
perspectives and challenges (Figure 2):  
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 Diagnosis is the first step, but it is not always easy as certain diseases may overlap (e.g. 
wheezing in preschool children). 
 Control should be monitored in all patients with a diagnosis of chronic allergic disease using 
available tests. Control should be regularly evaluated and treatment adapted to its level.  
 Responsiveness to treatment is the ease with which disease control is achieved by therapeutic 
interventions. For asthma or allergic rhinitis, effective treatments are available for most patients. 
Some diseases (e.g. some phenotypes of non-allergic rhinitis or urticaria) are more difficult to 
control. 
 Availability and affordability of the treatment: The management of allergic disease 
depends on the context of national (or regional), economic and health provider settings and 
facilities, the health system as well as individual and societal variables (beliefs, cultural and socio-
economic determinants). In high-income countries, treatments are available and, for most patients, 
affordable. However, in many LMICs and in some deprived areas of high-income countries, 
essential medicines may be available but are rarely affordable (50) although they should be in 
formularies. Even if medications are affordable, health professional knowledge concerning their 
optimal use is fragmented and requires training. Furthermore, the health system often lacks 
infrastructure for early diagnosis, follow up and education as well as legislation for appropriate 
referral.   
 Re-assessment of the diagnosis of the disease: In patients who are uncontrolled despite 
optimal treatment, all reasonable efforts to eliminate other diagnoses must be made. Patients may 
suffer from a mild disease that is considered to be severe because it is underlined by another 
disease (e.g. wheezing in cystic fibrosis). It may be difficult to ascribe the differential severity to 
the allergic disease or the underlying one. On the other hand, there may be a degree of 
overdiagnosis which could lead to a false impression of severe disease. 
 Difficult-to-treat severe disease represents a category in which partial or poor response to 
treatment reflects factors other than the disease alone. Issues to address in such cases include: 
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• Poor adherence to treatment.  
• Incorrect inhalation technique. 
• Adverse environmental circumstances such as passive smoke or allergen exposure. 
• Psychosocial issues.  
• And co-morbidities which cannot be controlled.  
Any or all of these factors can be very important in any chronic disease. 
 Patients with treatment-dependent severe disease are those who require the highest level 
of recommended treatment to maintain control. This requirement for high doses of medication 
and multiple medications suggests a component of treatment resistance or insensitivity.  Although 
the disease is controlled, the patients are at risk of exacerbations if treatment is inappropriately 
reduced or becomes unavailable.  
 Patients with treatment-resistant severe disease are those who are partially or poorly 
controlled despite the highest recommended treatment provided according to the guidelines 
existing in the country (or if guidelines do not exist, the highest controller medications available in 
the country). This insensitivity may not be an absolute phenomenon, but varies from patient to 
patient and with time.   
 Severity should be re-assessed at regular intervals as it may change over time.  
3.  Severe allergic and related diseases 
3.1. Allergic and non-allergic rhinitis (and rhino-conjunctivitis) 
 
Allergic rhinitis is an IgE-mediated reaction of the nasal mucosa. It is often associated with 
conjunctivitis (rhino-conjunctivitis) (11). Non-allergic rhinitis represents a group of heterogeneous 
diseases in which no IgE-mediated reaction can be demonstrated (17). Unmet clinical needs are clear 
in allergic and non-allergic rhinitis (51). 
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3.1.1. Control 
Control and severity are not well delineated in rhinitis. Using the new definition, measures of the 
control of allergic rhinitis include symptom scores, visual analogue scales (VAS) (52), objective 
measures of nasal obstruction such as peak inspiratory flow measurements, acoustic rhinometry and 
rhinomanometry (53), a recent modification of the ARIA severity classification (54), or patients’ 
reported outcomes such as quality-of-life (11, 55, 56). More recently, a score with several items was 
proposed (57). It appears in rhinitis that a simple measure such as VAS may be sufficient to appreciate 
the control of the disease (58) and is particularly relevant to primary (59) or pharmacy care (60). The 
level of control of allergic rhinitis is assessed independent of the treatment step (52, 61).   
3.1.2. Responsiveness to treatment 
Most patients with allergic rhinitis can be controlled using guideline-based treatment. However, 
among patients with moderate to severe symptoms who comply with an adequate treatment according 
to guidelines, up to 20% continue to be impaired by their symptoms. The GA²LEN-ARIA-WAO task 
force has proposed the new appellation of Severe Chronic Upper Airways Disease (SCUAD) for these 
cases where patients’ symptoms are not sufficiently controlled despite their pharmacological treatment 
(51, 62). However, SCUAD applies to all nasal diseases irrespective of the allergic component. 
Allergic conjunctivitis is frequently associated with pollen-induced rhinitis but it is more difficult to 
control than rhinitis (63). 
The efficacy of the treatment of non-allergic rhinitis is variable (17). It is heterogeneous in etiologies 
and inconsistently benefits from treatments which are effective in allergic rhinitis (64, 65).   
3.1.3. Re-assessment of the diagnosis of the disease 
Many different conditions can mimic allergic and non-allergic rhinitis (66). Local allergic reactions 
with nasal but not systemic IgE antibodies (67) may be more important than initially thought. 
Misdiagnosis (e.g. nasal tumors, granulomas, cerebrospinal rhinorrhea) may lead to adverse outcomes 
if the patient is not appropriately re-assessed and reviewed. 
3.1.4. Risk 
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Allergic rhinitis impairs work (68, 69) and school performance (70, 71). Moreover, sedation may be 
enhanced using H1-antihistamines with sedative properties (72). The major long-term risk of allergic 
and non-allergic rhinitis is the development of asthma (73). 
3.2. Chronic rhinosinusitis (CRS) 
3.2.1. Control 
Control and severity are not well delineated in CRS. Using the new definition, it is proposed that  an 
overall symptom score measured by VAS may more accurately monitor control, and could be 
combined with  disease specific (18, 74) and generic health status assessment instruments (18). 
3.2.2. Responsiveness to treatment 
Responsiveness to treatment differs in CRS without nasal polyps (CRSsNP) and in CRS with nasal 
polyps (CRSwNP) (75-77). The principle of SCUAD also applies to CRS (51). 
The pathophysiology of CRSsNP is poorly understood (19) and treatment options are limited to 
topical corticosteroids (18). According to clinical experience and reports, sinus surgery improves 
symptoms in the short-term in 65-90% of the cases.  
In CRSwNP, symptoms may be controlled by topical corticosteroid treatment in mild to moderate 
localized disease (78-80). However, in severe polyposis and asthma co-morbidity, repeated courses of 
intranasal and/or oral corticosteroids are usually insufficient in controling symptoms. Repeated sinus 
surgeries may be needed with inconsistent clinical benefits (81).      
3.2.3. Re-assessment of the diagnosis of the disease 
The differential diagnosis includes all forms of rhinitis, as well as underlying sinus diseases such as 
cystic fibrosis, primary ciliary dyskinesia, non-invasive fungal sinusitis, allergic fungal sinus disease 
and invasive forms (18). Sinus headache needs to be differentiated from neurological, ocular or facial 
pains. Other rare diagnoses are Wegener´s, other granulomas disease, cocaine abuse or lymphomas. 
Any unilateral obstruction, pain and bleeding has to be investigated by a specialist to exclude 
malignancies, inverted papilloma, meningoceles and other serious conditions (82). 
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3.2.4. Risk 
Very rarely, acute complications with a spread of the disease into the orbit, the meninges, the brain or 
frontal bone (osteomyelitis) may develop in the course of acute exacerbations of the disease. 
Mucoceles develop slowly as long-term complications after surgery, but can also develop 
spontaneously.   
About 10-15% of the CRSsNP and up to 45% of the CRSwNP patients present or will develop co-
morbid asthma, which may be severe (83). CRSwNP may also develop into a systemic disease such as 
aspirin-exacerbated respiratory disease (84), or Churg-Strauss syndrome (85). Allergic fungal sinus 
disease may be accompanied by allergic bronchopulmonary aspergillosis (ABPA).   
Repeated courses of oral corticosteroids in patients with persistent CRS may affect bone metabolism 
and lead to HPA-axis dysfunction (79, 86). 
3.3. Chronic urticaria 
Urticaria describes the spontaneous or inducible occurrence of wheals and flares often accompanied 
by pruritus which generally subside within hours, while new lesions occur. Chronic urticaria is a group 
of spontaneous or inducible diseases characterized by symptom persistence or reoccurence over 6 
weeks (21, 87) with several clinical unmet needs (88). Angioedema describes a deep swelling in the 
dermis which can be accompanied by pain and predominantly involves soft tissues, e.g. in the face 
(eyelids, lips) or genital area. 
3.3.1. Control 
Control and severity are not well delineated in chronic urticaria (88). Using the new definition, control 
can be assessed by the daily number of wheals and by the intensity of the pruritus as assessed using 
the weekly urticaria activity score (UAS7) (89) and/or the chronic urticaria quality of life 
questionnaire (CU-Q2oL) (90, 91). Patient diaries and health-related quality of life instruments can be 
used. 
3.3.2. Responsiveness to treatment 
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In chronic urticaria, symptomatic treatment is the rule since causal treatment is rarely effective (22, 
88). Chronic urticaria can be fully controlled in a minority of  patients by following the guideline-
recommended step-up approach. The aim of the treatment in chronic urticaria is the absence of 
symptoms, i.e. the complete protection from the reoccurrence of wheals, pruritus, and angioedema. 
This can be achieved in less than half of all patients by using licensed doses of non-sedating oral H1-
antihistamines, the guideline-recommended first step therapy and only in-label treatment option (92).   
3.3.3. Re-assessment of the diagnosis of the disease 
Urticaria vasculitis and auto-inflammatory disorders (e.g. cryopyrin-associated periodic syndrome 
(CAPS) (93), Schnitzler syndrome (94)), mastocytosis (95) and hereditary or other complement 
associated disease (8) must be considered in patients with chronic spontaneous urticaria who present 
with wheals and signs of systemic inflammation or recurrent angioedema without wheals. These 
diseases are associated with a high risk of severe morbidity and mortality. 
3.3.4. Risk 
The risks in chronic inducible urticaria are different from those in chronic spontaneous urticaria and 
are specific for each inducible urticaria. In general, low thresholds for trigger intensity and for trigger 
exposure time are indicators of high disease activity (96).  
Some inducible urticarias such as cold urticaria and exercise-induced urticaria can induce severe 
systemic reactions including anaphylactic shock which may lead to death (e.g. swimming in cold 
water). 
Chronic spontaneous urticaria patients are at risk of developing comorbidities such as autoimmune 
disorders (e.g. autoimmune thyroiditis) (97). 
Since many patients cannot be controlled using recommended doses of medications, uncontrolled 
patients often develop depression and anxiety (98).  
Many chronic urticaria patients are at risk of experiencing adverse effects of their therapy since they 
often receive doses higher than those recommended as well as the off-label use of other medications.  
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3.4. Atopic dermatitis 
3.4.3. Control 
Several severity tests of current atopic dermatitis (AD) have been published. Three measurements 
(SCORing Atopic Dermatitis [SCORAD] (99), Eczema Area and Severity Index [EASI] (100), and 
Patient-oriented Eczema Measure [POEM]) have been tested sufficiently and performed adequately 
(101). Other scoring systems such as the Langeland-Rajka score have been designed to include 
information about the recent past (3 months) of the disease (102). Besides the objective parameters 
such as erythema or excoriations, the more subjective aspect of pruritus/itching is of great importance 
in the evaluation of the disease since it also reflects the severity. SCORAD also includes a VAS 
component for this particular symptom. Furthermore, SCORAD has been used to classify AD into 3 
main severity forms: mild (<15), moderate (>15 and <40) and severe (>40). Recently, a patient-
oriented version of SCORAD (PO-SCORAD) was proposed and validated, allowing the estimation of 
severity by the patients themselves or the caregivers of affected children (103). These scoring systems 
only provide a snapshot of the current disease situation for a given patient at a defined time point 
(104) and should be more appropriately considered as control tests. 
Impaired QOL is common in AD, both in children (patients and caregivers) and adults. Impaired QOL 
may be observed in infants (105). Several QOL measures (disease-specific and generic) have been 
used (106).  
  
3.4.4. Responsiveness to treatment 
Most cases of patients seemingly resistant to the treatment are certainly explained by a lack of correct 
implementation of the guidelines (107, 108). This can be improved by an intense treatment under 
supervision and adapted educational programs. Thus, as in other chronic diseases, the responsiveness 
and control of the disease is tightly dependent on the compliance of the patients/parents. However, 
truly therapy-resistant AD severe cases exist, which may be explained by a particular genetic 
predisposition. There are currently no studies available having addressed this issue, but it is estimated 
that no more than 5% of AD belong to this group (13). 
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3.4.5. Re-assessment of the diagnosis of the disease   
Depending on the age of onset, AD can be misdiagnosed (107, 108). In preschool children, the 
spectrum of differential diagnosis is very wide including either common diseases such as psoriasis or 
rather rare conditions such as Schwachman Diamond's syndrome (also named Burke-Syndrome) 
agammaglobulinaemia, ataxia telangiectasia (109) and histiocytic disorders (110). In adults, other 
diseases such as seborrheic dermatitis  or cutaneous T cell lymphoma have to be excluded (111). 
3.4.6. Risk 
Atopic dermatitis during infancy is a risk factor for other atopic diseases occurring later in childhood 
(112-114). This is probably the case for about 30% of AD patients, mostly with early onset, i.e. in 
infancy. During the first year of life, atopic dermatitis is mostly related to food allergy, but very often 
spontaneously improves after one to two years. Children with early onset, a filagrin mutation and 
having food allergy (mainly peanut) have almost a 100% risk of developing allergic asthma (115).  
On the other hand, about 30% of adult patients seem to develop specific IgE against self-proteins, 
suggesting an autoimmune form of AD in adulthood for which allergen avoidance is therefore 
meaningless (116).  
Due to a strongly impaired innate immunity response of the epidermal barrier in AD, these patients 
have a high risk of developing superinfections with bacteria such as Staphylococcus aureus, fungi 
such as Malassezia sympodialis or herpes simplex virus  or causing eczema herpeticum, a severe 
complication of AD (117, 118).  
The increased permeability of the skin associated with chronic inflammation may also favor 
sensitization to haptens, causing increasing rates of allergic contact dermatitis (119). 
4. Application to children 
4.1 Severe problematic asthma 
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Severe problematic asthma is probably as common in children as in adults, with approximately 4-5 % 
of children with asthma (120). Phenotypes of severe problematic asthma differ in children and in 
adults (121, 122). A proposal with a 4-step procedure for the diagnosis and assessment of severe 
problematic asthma in childhood has recently been published (123). The steps include (a) a full 
diagnostic work-up that may exclude other chronic lung diseases which may mimic severe asthma; (b) 
a multidisciplinary assessment to identify factors of importance including co-morbidities; (c) an 
assessment of the pattern of inflammation and (d) a documentation of the level of corticosteroid 
responsiveness. 
 4.2 Allergic rhinoconjunctivitis and chronic rhinosinusitis 
For children, there is an increasing awareness that rhinitis may start in very early childhood, but 
definitions and control measures are largely lacking. Treatment challenges are frequently more 
pronounced in children, with sparse documentation of pharmacological intervention in severe disease, 
which is often part of complex atopic disease presentation. 
It is difficult to diagnose allergic rhinitis/conjunctivitis in preschool children. Furthermore, children of 
this age have frequent infections of the upper airways, and management is challenging due to a lack of 
guidelines, co-morbidities and a lack of objective parameters to guide diagnosis.  
There are specific problems in childhood/adolescence such as general symptoms of malaise occurring 
during important school and university examinations in the spring pollen season (124). 
In children, it may be difficult to distinguish between persistent non-allergic rhinitis and rhinitis 
associated with recurrent respiratory tract infections. 
Cystic fibrosis or primary ciliary dyskinesias are important to rule out in patients suspected of chronic 
rhinosinusitis. 
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5.  Importance of a uniform approach  
5.1. Subphenotyping severe/uncontrolled diseases 
Allergic diseases represent complex multi-dimensional diseases with marked heterogeneity depending 
on environmental factors and socio-economic determinants. Tools to phenotype individual disease 
subtypes are now being developed in order to characterize the various patterns of triggers that induce 
symptoms, different clinical presentations of the disease, and different inflammatory markers. This is 
the case for asthma (US SARP: Severe Asthma Research Program (125, 126), U-BIOPRED, (45, 127) 
and allergic disease onset (MeDALL, Mechanisms of the Development of ALLergy, FP7, (49)) but 
more research is needed to identify allergic disease subphenotypes or endophenotypes (128) based on 
severity.  
Phenotyping subtypes can be used to characterize and predict disease severity, progression, and 
response to treatment, and may help identify unique targets for treatment (26). Heterogeneity also 
exists within each dimension of the disease (e.g. eosinophils and asthma severity) (129, 130), across 
diseases (e.g. eosinophils in asthma and COPD) and in relation to co-morbidities (131, 132). 
Phenotypes may also change over time. 
Phenotype heterogeneity may reflect a priori defined hypotheses or lead to the generation of novel 
hypotheses through multiple logistic regression (131, 133), cluster analysis (126, 132) or free scale 
networks. However, a uniform definition applied worldwide is needed, and then detailed 
subphenotyping of severe allergic diseases may be approached (28).  
5.2. Clinical practice  
A uniform definition provides a framework to decide who needs targeting for treatment or improved 
treatment (28).  It will help in the delivery of appropriate health care through better organization for 
diagnosis and treatment in primary care and/or specialist clinics. A multidisciplinary approach is 
recommended in patients with severe allergic diseases (39). For this, the use of a common language 
across primary, secondary and tertiary care is important. A major challenge is that their functional 
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differentiation of level of care turns into a segregation of patient flows. The use in guidelines of the 
same definitions and criteria across the board of health care will facilitate a smooth transfer of patients 
from primary care to more specialized care and back, according to their needs. Communication with 
patients or parents of patients should be focused on providing information on the need for therapy and 
the consequent use of therapy, as well as on the risks of not complying with these recommendations. 
5.3. Personalized medicine  
The main challenge for allergic diseases in the 21
st
 century is to understand their complexity. 
Identification of the underlying mechanisms will help the prognosis, diagnosis and treatment of 
disease (49) as well as the transition to predictive, preventive, personalized and participatory (P4) 
medicine (134). The uniform approach of severity is perfectly embedded within this new paradigm. 
5.4. Registries for severe allergic (and related) diseases 
Severe asthma registries provide a foundation upon which to generate a greater understanding of 
public health needs, to define phenotypic heterogeneity to inform the design of research studies and to 
improve overall clinical care (28). Registries will help in the surveillance of severe allergic diseases. 
Data from the registries may provide evidence of inadequacies in the control of diseases. The 
establishment of an internationally-agreed definition of severe allergic (and related) diseases will 
provide the opportunity to develop a single registry in order to capture core information in both 
developed and developing countries. This is particularly relevant to the worldwide changing 
demography of allergic diseases.   
5.5. Clinical trials 
For clinical trials, it is essential to have clarity as to what definitions have been used - severity 
assessed before treatment or after treatment, and in this case, which treatment was used. In addition, 
clinical trials should consider co-morbidities and confounding conditions necessary for the adequate 
assessment of clinical responses (e.g. smoking and asthma) or effectiveness of different therapeutic 
approaches.    
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5.6. Registration of medicines and reimbursement 
Controlled trials designed with a uniform approach of severity (135) will be more easily evaluated by 
the agencies for approval and by the Health Technology Assessment agencies (such as NICE) for 
reimbursement.  
5.7. Research on mechanisms and genetics 
More research into severe allergic diseases is urgently needed. Many large collaborative studies are 
already ongoing for severe asthma (125-127), but not for the other diseases. A uniform definition and 
a collaborative approach to epidemiological, genetic and mechanistic research are important. Different 
levels of phenotype characterization (granularity) can be applied to assess phenotypic characterization 
in patients with severe allergic (and related) diseases. For the success of such approaches, it is 
important to develop global partnerships and platforms to ensure the application of standard 
methodology and protocols to promote the collection and sharing of samples and data through 
appropriate infrastructure in different countries (28). 
5.8. Epidemiology 
In epidemiologic population studies, standardized definitions are fundamental. It is often difficult to 
assess severity since many patients are undertreated. The uniform definition of severe allergic (and 
related) diseases accounts for these patients and articulates time frames for the appropriate assessment 
of severity and control. Thus, the definition will facilitate epidemiological research, understand 
modifiable risk factors and enable comparisons across studies in different populations. Control usually 
refers to events occurring recently (over the last 2-4 weeks) whereas severity refers to those occurring 
over a long period of time (e.g. 6-12 months).   
5.9. Public health planning 
For public health purposes, a uniform definition of severe allergic (and related) diseases is needed to 
identify the prevalence, burden and costs incurred by severe patients in order to improve quality of 
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care and optimize health care planning and policies. This definition will provide support for more 
precise calculations on the needs and costs of medications in a country.   
5.10. Developed and developing countries 
A uniform definition of severe allergic (and related) diseases should be applicable to the local and 
geographical conditions of all countries, phenotypes, risk factors, availability and affordability to 
treatment differing widely around the world. Research must be planned to evaluate the phenotypes of 
“severe” allergic (and related) diseases from different countries.  
5.11. Development of novel therapies 
For treatment-resistant severe allergic (and related) diseases, more detailed cellular and molecular 
phenotyping is needed to identify new targets for the development of novel therapies and to improve 
current therapies in a cost-effective manner. Ultimately, novel therapies studied in clinical trials 
should help define the pathogenesis of the diseases and determine the importance of the treatment in 
large patient populations or in sub-populations of patients based on the concept of distinct phenotypes. 
Conclusions 
It is likely that a uniform definition of severe allergic diseases will help in a better understanding of 
phenotypes but there is a need for a validation process of the proposed definition for severe chronic 
allergic diseases across different populations and countries with different income, age groups and 
different disease phenotypes. 
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Table I: Goals of the current paper 
 The current document develops a common strategy to the severity of chronic allergic (and related) diseases 
taken individually. 
 It does not consider acute allergic reactions such as anaphylaxis. 
 It does not take into account co-morbidities (29). 
 It is intended to be used by all stakeholders involved in the management or research of allergic (and related) 
diseases. 
  
Table 2: Components contributing to asthma severity  
From (23) and (28) 
1- Level of control  
 Current clinical control (impairment): Symptoms, health status and functional limitations over previous 2-4 weeks 
 Severe exacerbations over previous 6-12 months (use of oral or systemic corticosteroids) 
2- Level of current treatment prescribed 
3- Inhalation technique and compliance to treatment 
4- Responsiveness to treatment 
5- Exposure to aggravating factors 
6- Risk  
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Table 3: Level of asthma control in patients ≥ 5 years of age 
From (28) (Adapted from GINA 2006  (31) and  2007 NAEPP-EPR3 (23)) 
Any of the components places the patient in the category   
Control level  Well controlled** Partially controlled** Poorly controlled** 
Daytime symptoms in the past 2-4 
weeks 
≤ 2 days / week but not 
more than once a day 
> 2 days / week  
Or more than once a day 
but ≤ 2 days / week 
Throughout the day 
Limitations of activities in the past 2-4 
weeks 
None Some limitation Extremely limited 
Nocturnal symptoms/awakenings in the 
past 2-4 weeks 
None ≤ 2 nights / week > 2 nights / week 
Need for short-acting inhaled ß2-
agonists in the past 2-4 weeks 
≤ 2 days per week > 2 days per week Several times a day 
Lung function  
 FEV1 or PEFR* 
FEV1/FVC (<11 yrs of age) 
 
≥ 80% predicted or personal 
best ≥ 80% 
 
60-79% predicted or 
personal best 75-79% 
 
<60% predicted or 
personal best <75% 
Exacerbation(s) (requiring oral or 
systemic corticosteroids)*** 
0-1/ yr 2/yr Frequent  (>2/yr)  
Consider severity and interval since last exacerbation  
*: FEV1 or PEF may be ≥ 80% predicted in patients with severe persistent asthma 
**: * For well controlled asthma, all components should be present; for partially or poorly controlled asthma, any of the components places 
the patient in the category   
***: At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control of severity.  
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Figure 1: Evaluation of asthma severity (from (23)) 
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Figure 2: Uniform approach for the definition of severe allergic (and related) diseases 
(adapted from (49)) 
 
